Review



scd40 levels  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    R&D Systems scd40 levels
    CD40 gene expression and <t>sCD40</t> levels according to −1 C > T (rs1883832) and 6,048 G > T (rs4810485) polymorphisms. (a) CD40 gene expression in CS and SLE patients, (b) sCD40 levels in CS and SLE patients, (c) and (d) sCD40 levels according to −1 C > T (rs1883832) and 6,048 G > T (rs4810485) genotypes; (e) CD40 gene expression according to dominant model of −1 C > T (rs1883832) polymorphism in SLE patients, and (f) sCD40 levels according to dominant model of −1 C > T (rs1883832) polymorphism in SLE patients. The qualitative gene expression analysis was obtained through to Pfaffl's method. Mann‐Whitney U test, Kruskal‐Wallis test, and Dunn's post hoc test were used. Fc was obtained through the 2 ‐ΔΔCq method. Data are shown in median and IQR. CS: Control subjects, Fc: Fold change, IQR: Interquartile range, SLE: Systemic Lupus Erythematosus
    Scd40 Levels, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 28 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/scd40 levels/product/R&D Systems
    Average 92 stars, based on 28 article reviews
    scd40 levels - by Bioz Stars, 2026-04
    92/100 stars

    Images

    1) Product Images from "Association of soluble CD40 levels with ‐1 C > T CD40 polymorphism and chronic kidney disease in systemic lupus erythematosus"

    Article Title: Association of soluble CD40 levels with ‐1 C > T CD40 polymorphism and chronic kidney disease in systemic lupus erythematosus

    Journal: Molecular Genetics & Genomic Medicine

    doi: 10.1002/mgg3.1014

    CD40 gene expression and sCD40 levels according to −1 C > T (rs1883832) and 6,048 G > T (rs4810485) polymorphisms. (a) CD40 gene expression in CS and SLE patients, (b) sCD40 levels in CS and SLE patients, (c) and (d) sCD40 levels according to −1 C > T (rs1883832) and 6,048 G > T (rs4810485) genotypes; (e) CD40 gene expression according to dominant model of −1 C > T (rs1883832) polymorphism in SLE patients, and (f) sCD40 levels according to dominant model of −1 C > T (rs1883832) polymorphism in SLE patients. The qualitative gene expression analysis was obtained through to Pfaffl's method. Mann‐Whitney U test, Kruskal‐Wallis test, and Dunn's post hoc test were used. Fc was obtained through the 2 ‐ΔΔCq method. Data are shown in median and IQR. CS: Control subjects, Fc: Fold change, IQR: Interquartile range, SLE: Systemic Lupus Erythematosus
    Figure Legend Snippet: CD40 gene expression and sCD40 levels according to −1 C > T (rs1883832) and 6,048 G > T (rs4810485) polymorphisms. (a) CD40 gene expression in CS and SLE patients, (b) sCD40 levels in CS and SLE patients, (c) and (d) sCD40 levels according to −1 C > T (rs1883832) and 6,048 G > T (rs4810485) genotypes; (e) CD40 gene expression according to dominant model of −1 C > T (rs1883832) polymorphism in SLE patients, and (f) sCD40 levels according to dominant model of −1 C > T (rs1883832) polymorphism in SLE patients. The qualitative gene expression analysis was obtained through to Pfaffl's method. Mann‐Whitney U test, Kruskal‐Wallis test, and Dunn's post hoc test were used. Fc was obtained through the 2 ‐ΔΔCq method. Data are shown in median and IQR. CS: Control subjects, Fc: Fold change, IQR: Interquartile range, SLE: Systemic Lupus Erythematosus

    Techniques Used: Expressing, MANN-WHITNEY

    CD40 gene expression and sCD40 levels according to SLE activity. (a) CD40 gene expression according to disease activity (b) sCD40 levels according to disease activity, (c) sCD40 levels and SLICC damage index correlation, (d) sCD40 levels and eGFR correlation, (e) association between sCD40 levels and KDIGO stage, and (f) sCD40 levels and CKD (SLE patients with an eGFR < 50ml/min/1.73m2). The qualitative gene expression analysis was obtained through to Pfaffl's method. Mann‐Whitney U test, Kruskal‐Wallis test, Dunn's post hoc test, and Spearman rank correlation coefficient were used, Fc was obtained through the 2 ‐ΔΔCq method. Data are shown in median and IQR. CS: Control Subjects, CKD: Chronic Kidney Disease, eGFR: estimated Glomerular Filtration Rate, KDIGO: Kidney Disease Improving Global Outcomes, Fc: Fold change, IQR: Interquartile range, SLE: Systemic Lupus Erythematosus
    Figure Legend Snippet: CD40 gene expression and sCD40 levels according to SLE activity. (a) CD40 gene expression according to disease activity (b) sCD40 levels according to disease activity, (c) sCD40 levels and SLICC damage index correlation, (d) sCD40 levels and eGFR correlation, (e) association between sCD40 levels and KDIGO stage, and (f) sCD40 levels and CKD (SLE patients with an eGFR < 50ml/min/1.73m2). The qualitative gene expression analysis was obtained through to Pfaffl's method. Mann‐Whitney U test, Kruskal‐Wallis test, Dunn's post hoc test, and Spearman rank correlation coefficient were used, Fc was obtained through the 2 ‐ΔΔCq method. Data are shown in median and IQR. CS: Control Subjects, CKD: Chronic Kidney Disease, eGFR: estimated Glomerular Filtration Rate, KDIGO: Kidney Disease Improving Global Outcomes, Fc: Fold change, IQR: Interquartile range, SLE: Systemic Lupus Erythematosus

    Techniques Used: Expressing, Activity Assay, MANN-WHITNEY, Filtration



    Similar Products

    scd40 levels  (R&D Systems)
    92
    R&D Systems scd40 levels
    CD40 gene expression and <t>sCD40</t> levels according to −1 C > T (rs1883832) and 6,048 G > T (rs4810485) polymorphisms. (a) CD40 gene expression in CS and SLE patients, (b) sCD40 levels in CS and SLE patients, (c) and (d) sCD40 levels according to −1 C > T (rs1883832) and 6,048 G > T (rs4810485) genotypes; (e) CD40 gene expression according to dominant model of −1 C > T (rs1883832) polymorphism in SLE patients, and (f) sCD40 levels according to dominant model of −1 C > T (rs1883832) polymorphism in SLE patients. The qualitative gene expression analysis was obtained through to Pfaffl's method. Mann‐Whitney U test, Kruskal‐Wallis test, and Dunn's post hoc test were used. Fc was obtained through the 2 ‐ΔΔCq method. Data are shown in median and IQR. CS: Control subjects, Fc: Fold change, IQR: Interquartile range, SLE: Systemic Lupus Erythematosus
    Scd40 Levels, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/scd40 levels/product/R&D Systems
    Average 92 stars, based on 1 article reviews
    scd40 levels - by Bioz Stars, 2026-04
    92/100 stars
    		  Buy from Supplier

    Image Search Results


    CD40 gene expression and sCD40 levels according to −1 C > T (rs1883832) and 6,048 G > T (rs4810485) polymorphisms. (a) CD40 gene expression in CS and SLE patients, (b) sCD40 levels in CS and SLE patients, (c) and (d) sCD40 levels according to −1 C > T (rs1883832) and 6,048 G > T (rs4810485) genotypes; (e) CD40 gene expression according to dominant model of −1 C > T (rs1883832) polymorphism in SLE patients, and (f) sCD40 levels according to dominant model of −1 C > T (rs1883832) polymorphism in SLE patients. The qualitative gene expression analysis was obtained through to Pfaffl's method. Mann‐Whitney U test, Kruskal‐Wallis test, and Dunn's post hoc test were used. Fc was obtained through the 2 ‐ΔΔCq method. Data are shown in median and IQR. CS: Control subjects, Fc: Fold change, IQR: Interquartile range, SLE: Systemic Lupus Erythematosus

    Journal: Molecular Genetics & Genomic Medicine

    Article Title: Association of soluble CD40 levels with ‐1 C > T CD40 polymorphism and chronic kidney disease in systemic lupus erythematosus

    doi: 10.1002/mgg3.1014

    Figure Lengend Snippet: CD40 gene expression and sCD40 levels according to −1 C > T (rs1883832) and 6,048 G > T (rs4810485) polymorphisms. (a) CD40 gene expression in CS and SLE patients, (b) sCD40 levels in CS and SLE patients, (c) and (d) sCD40 levels according to −1 C > T (rs1883832) and 6,048 G > T (rs4810485) genotypes; (e) CD40 gene expression according to dominant model of −1 C > T (rs1883832) polymorphism in SLE patients, and (f) sCD40 levels according to dominant model of −1 C > T (rs1883832) polymorphism in SLE patients. The qualitative gene expression analysis was obtained through to Pfaffl's method. Mann‐Whitney U test, Kruskal‐Wallis test, and Dunn's post hoc test were used. Fc was obtained through the 2 ‐ΔΔCq method. Data are shown in median and IQR. CS: Control subjects, Fc: Fold change, IQR: Interquartile range, SLE: Systemic Lupus Erythematosus

    Article Snippet: The sCD40 levels were determined using a commercial ELISA test (DCCD40 Quantikine ELISA kit [R&D Systems ® ]) according to manufacturer's conditions.

    Techniques: Expressing, MANN-WHITNEY

    CD40 gene expression and sCD40 levels according to SLE activity. (a) CD40 gene expression according to disease activity (b) sCD40 levels according to disease activity, (c) sCD40 levels and SLICC damage index correlation, (d) sCD40 levels and eGFR correlation, (e) association between sCD40 levels and KDIGO stage, and (f) sCD40 levels and CKD (SLE patients with an eGFR < 50ml/min/1.73m2). The qualitative gene expression analysis was obtained through to Pfaffl's method. Mann‐Whitney U test, Kruskal‐Wallis test, Dunn's post hoc test, and Spearman rank correlation coefficient were used, Fc was obtained through the 2 ‐ΔΔCq method. Data are shown in median and IQR. CS: Control Subjects, CKD: Chronic Kidney Disease, eGFR: estimated Glomerular Filtration Rate, KDIGO: Kidney Disease Improving Global Outcomes, Fc: Fold change, IQR: Interquartile range, SLE: Systemic Lupus Erythematosus

    Journal: Molecular Genetics & Genomic Medicine

    Article Title: Association of soluble CD40 levels with ‐1 C > T CD40 polymorphism and chronic kidney disease in systemic lupus erythematosus

    doi: 10.1002/mgg3.1014

    Figure Lengend Snippet: CD40 gene expression and sCD40 levels according to SLE activity. (a) CD40 gene expression according to disease activity (b) sCD40 levels according to disease activity, (c) sCD40 levels and SLICC damage index correlation, (d) sCD40 levels and eGFR correlation, (e) association between sCD40 levels and KDIGO stage, and (f) sCD40 levels and CKD (SLE patients with an eGFR < 50ml/min/1.73m2). The qualitative gene expression analysis was obtained through to Pfaffl's method. Mann‐Whitney U test, Kruskal‐Wallis test, Dunn's post hoc test, and Spearman rank correlation coefficient were used, Fc was obtained through the 2 ‐ΔΔCq method. Data are shown in median and IQR. CS: Control Subjects, CKD: Chronic Kidney Disease, eGFR: estimated Glomerular Filtration Rate, KDIGO: Kidney Disease Improving Global Outcomes, Fc: Fold change, IQR: Interquartile range, SLE: Systemic Lupus Erythematosus

    Article Snippet: The sCD40 levels were determined using a commercial ELISA test (DCCD40 Quantikine ELISA kit [R&D Systems ® ]) according to manufacturer's conditions.

    Techniques: Expressing, Activity Assay, MANN-WHITNEY, Filtration